Capital Fund Management S.A. Acquires 81,164 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Capital Fund Management S.A. lifted its position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 36.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 304,832 shares of the company's stock after buying an additional 81,164 shares during the quarter. Capital Fund Management S.A. owned about 0.25% of 10x Genomics worth $4,377,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. acquired a new position in 10x Genomics during the 4th quarter valued at $26,308,000. ARK Investment Management LLC raised its position in shares of 10x Genomics by 11.1% during the fourth quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company's stock valued at $171,517,000 after buying an additional 1,193,712 shares during the last quarter. SVB Wealth LLC acquired a new stake in 10x Genomics during the fourth quarter worth about $7,505,000. Trexquant Investment LP increased its stake in 10x Genomics by 196.2% during the fourth quarter. Trexquant Investment LP now owns 594,611 shares of the company's stock valued at $8,539,000 after acquiring an additional 393,854 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in 10x Genomics in the 4th quarter valued at approximately $5,557,000. Institutional investors own 84.68% of the company's stock.

10x Genomics Trading Down 6.5 %

Shares of 10x Genomics stock traded down $0.52 during midday trading on Friday, reaching $7.51. The company had a trading volume of 6,488,585 shares, compared to its average volume of 2,194,398. The stock has a fifty day simple moving average of $9.88 and a 200 day simple moving average of $13.52. 10x Genomics, Inc. has a 1-year low of $6.78 and a 1-year high of $29.45. The company has a market capitalization of $918.49 million, a price-to-earnings ratio of -4.94 and a beta of 2.01.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. Sell-side analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

Analyst Ratings Changes

TXG has been the topic of a number of research reports. Stifel Nicolaus lowered their price objective on 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th. UBS Group dropped their price objective on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating for the company in a research note on Thursday, February 13th. Morgan Stanley decreased their target price on shares of 10x Genomics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Barclays lowered their target price on shares of 10x Genomics from $15.00 to $12.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Finally, Citigroup cut their price target on shares of 10x Genomics from $20.00 to $15.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $19.79.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 5,092 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $56,368.44. Following the completion of the transaction, the chief executive officer now owns 879,482 shares in the company, valued at approximately $9,735,865.74. This represents a 0.58 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Alan Mateo acquired 40,000 shares of 10x Genomics stock in a transaction dated Friday, February 21st. The shares were purchased at an average cost of $11.14 per share, with a total value of $445,600.00. Following the completion of the transaction, the director now directly owns 61,691 shares of the company's stock, valued at $687,237.74. This trade represents a 184.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 10.03% of the company's stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.